Hubro Bioscience is a privately held biotech company devoted to the development and commercialisation of novel proprietary diagnostic tools for early detection and monitoring of cancer biomarkers in liquid biopsies.
– Jon Amund Eriksen, CEO Hubro Bioscience
The Hubro diagnostic tests identifies MSI cancer associated biomarkers and as such the patient population who would benefit from immunotherapy gives a good indication of the market for the diagnostic tests.
The global cancer immunotherapy market is expected to reach $111,098.5 million by 2025.
Hollingsworth, R. E. & Jansen, K. NPJ vaccines 4, 7, doi:10.1038/s41541-019-0103-y (2019).
The Company has a highly experienced international management and operational team, an extensive network of industrial and academic partners to optimise and leverage the development of its novel technology.
Founder and Chairman Of the Board of Directors / CEO Jon Amund Eriksen has established multiple cancer immunology companies and is a highly respected individual in the field of cancer vaccines.
Detection of cancer biomarkers in liquid biopsies allowing early treatment to improve prognosis and the quality of the lives of at-risk individuals and families.
Contact us
CEO Jon Amund Eriksen: jaeriksen@hubrobio.com